Answers are grounded in this paper and cite their sources.
Abstract BACKGROUND Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We sought to update our knowledge of ARCM in the trastuzumab era. METHODS This was a retrospective observational cohort study. A total of 2,959 patients with BC treated with anthracyclines in three regional cancer centers in Niigata City between 1990 and 2020 were included. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post- 2007 (late phase), corresponding to before and during the trastuzumab era in Japan. RESULTS The incidence of ARCM peaked at 6% in the 1990s, decreased, and remained at 2% until the 2010s. Mean anthracycline use in the early and late phases was 525 mg/m² and 307 mg/m² (P<0.001), and the 5-year survival rates were 28% and 45% (P=0.058), respectively. Human epidermal growth factor receptor type 2 (HER2) positivity with trastuzumab therapy in late phase was an independent predictor for mortality within 10 years (hazard ratio =0.24, 95% confidence interval: 0.10–0.56; P=0.001). At the end of the late phase, there were four times as many patients with ARCM as at the end of the early phase (twenty-six and six, respectively). Survivors of BC increased more rapidly in the late phase, though the rate of accumulation change was slight in the anthracycline-treated BC group and more pronounced in the ARCM group (P <0.001). CONCLUSIONS With increasing survivor with ARCM in the trastuzumab era, subtypes of HER2 positivity have gained significant importance in treating patients with ARCM in BC.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: